Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab for airway inflammation and mucus plugging in COPD
NL-OMON59096Phase 4Recruiting
- Sponsor
- Sanofi
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Dupilumab with Placebo (2 arms). Primary endpoint: Change from baseline to Week 24 in global lung mucus score. Started Feb 2026; status: recruiting.
02
Drugs
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON59096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59096.